Today marks Metastatic Breast Cancer Awareness Day — a day dedicated to honoring those living with advanced breast cancer and the families, researchers, and advocates working tirelessly to improve their care and outcomes.

We’re spotlighting an important discussion hosted by Susan G. Komen, featuring leading experts and patient voices who share insights on the challenges, hope, and scientific progress surrounding metastatic breast cancer (MBC).

Watch the full Komen discussion here: https://hubs.la/Q03NkZXY0

Why This Conversation Matters

For patients with metastatic breast cancer, awareness and early detection remain critical — especially as cancer can spread to the central nervous system (CNS) in the form of leptomeningeal metastases (LM), a rare but devastating complication that affects thousands each year.

At CNSide Diagnostics, we share Susan G. Komen’s commitment to advancing both understanding and innovation in metastatic disease. Through our proprietary CNSide® Cerebrospinal Fluid (CSF) Assay Platform, we aim to provide physicians with precise, real-time data that can help:

• Detect and quantify tumor cells within the CSF
• Support more informed clinical decisions
• Enable ongoing monitoring of treatment response

By combining molecular science with compassionate purpose, CNSide is helping shape the future of precision diagnostics in neuro-oncology and metastatic cancer care.

Our Shared Mission: Collaboration for Impact

Awareness days like today remind us that progress depends on partnership — between scientists, clinicians, and patients — working together to drive real change in metastatic cancer detection and treatment.

Learn more about CNSide’s work in advancing precision diagnostics for CNS cancers at www.cnside-dx.com.